VINORELBINE AN vinorelbine (as tartrate) 10 mg/1 mL concentrated injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

vinorelbine an vinorelbine (as tartrate) 10 mg/1 ml concentrated injection vial

amneal pharma australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg (equivalent: vinorelbine, qty 10 mg) - injection, concentrated - excipient ingredients: water for injections - treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as a first line treatment for advanced non-small cell lung cancer, as a single agent or in combination.

Vinorelbine 10mg/1ml concentrate for solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vinorelbine 10mg/1ml concentrate for solution for infusion vials

medac uk - vinorelbine tartrate - solution for infusion - 10mg/1ml

Vinorelbine 50mg/5ml concentrate for solution for infusion vials United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

vinorelbine 50mg/5ml concentrate for solution for infusion vials

medac uk - vinorelbine tartrate - solution for infusion - 10mg/1ml

NAVELBINE ORAL vinorelbine 80mg (as tartrate) capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

navelbine oral vinorelbine 80mg (as tartrate) capsule blister pack

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 110.8 mg (equivalent: vinorelbine, qty 80 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

NAVELBINE ORAL vinorelbine 20mg (as tartrate) capsule blister pack Australia - English - Department of Health (Therapeutic Goods Administration)

navelbine oral vinorelbine 20mg (as tartrate) capsule blister pack

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 27.7 mg (equivalent: vinorelbine, qty 20 mg) - capsule, soft - excipient ingredients: ethanol; purified water; glycerol; macrogol 400; gelatin; iron oxide yellow; titanium dioxide; medium chain triglycerides; ascorbyl palmitate; phosphatidyl choline; dl-alpha-tocopherol; sorbitol; 1,4-sorbitan; mannitol; hydrogenated starch hydrosylate; hypromellose; propylene glycol; isopropyl alcohol; aluminium chloride; sodium hydroxide; cochineal - non-small cell lung cancer: navelbine oral is indicated for first line treatment of advanced non-small cell lung cancer, as a single agent or in combination.,breast cancer: navelbine oral is indicated for the treatment of advanced breast cancer after failure of standard therapy as a single agent or in combination.

NAVELBINE vinorelbine 50mg/5mL (as tartrate) injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

navelbine vinorelbine 50mg/5ml (as tartrate) injection vial

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

NAVELBINE vinorelbine 10mg/mL (as tartrate) injection vial Australia - English - Department of Health (Therapeutic Goods Administration)

navelbine vinorelbine 10mg/ml (as tartrate) injection vial

pierre fabre australia pty ltd - vinorelbine tartrate, quantity: 13.85 mg/ml (equivalent: vinorelbine, qty 10 mg/ml) - injection, concentrated - excipient ingredients: water for injections - navelbine is indicated for the treatment of advanced breast cancer after failure of standard therapy, as a single agent or in combination; and as first line treatment for advanced non-small cell lung cancer, as a single agent or in combination. navelbine is indicated for the treatment, in combination with cisplatin, of patients with completely resected non-small cell lung cancer of stage ib or greater.

Teva Vinorelbine 50 Namibia - English - Namibia Medicines Regulatory Council

teva vinorelbine 50

teva pharmaceuticals (pty) ltd - vinorelbine tartararte - injection - each vial contains; vinorelbine tartrate equivalent to vinorelbine 50 mg

Vinorelbine Kabi Australia - English - Department of Health (Therapeutic Goods Administration)

vinorelbine kabi

fresenius kabi australia pty limited - vinorelbine tartrate -

Navelbine New Zealand - English - Medsafe (Medicines Safety Authority)

navelbine

new zealand medical & scientific ltd - vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg - soft gelatin capsule - 20 mg - active: vinorelbine tartrate 27.7mg equivalent to vinorelbine 20 mg excipient: edible ink red ethanol gelatin glycerol   anidrisorb 85/70 85% phosal 53 mct iron oxide yellow macrogol 400 medium-chain triglycerides purified water   titanium dioxide - first line treatment of advanced non-small cell lung cancer (nsclc) as a single agent or in combination